Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
about
Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysisBiomarkers in triple negative breast cancer: A reviewTriple-negative breast cancer: is there a treatment on the horizon?Point success rate for patient therapeutic response prediction by continuous biomarker scores.Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancersFavorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeHydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer.Circulating tumor cells in non-metastatic triple-negative breast cancer.ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approachesMost basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patientsDetection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinomaCharacteristics of triple-negative breast cancerClassifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.The human keratins: biology and pathology.Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.Significance of rat mammary tumors for human risk assessment.Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women.Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.Translational pathology of neoplasia.BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1Hormone receptors and age distribution in breast cancer patients at a university hospital in northern egyptGene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesisInvasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.Loss of post-transcriptional regulation of DNMT3b by microRNAs: a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines.Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.Will molecular classification replace traditional breast pathology?Basal phenotype breast cancer: implications for treatment and prognosis.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Triple negative breast cancer: the kiss of death.Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.Long noncoding RNAs (lncRNAs) in triple negative breast cancer.Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee.Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.Characterization of type III TGF-β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer.Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.Complexity in regulation of microRNA machinery components in invasive breast carcinoma.
P2860
Q21261291-C89912FC-2D33-43BD-862C-9C89AF997095Q26752303-AA008A0D-AD69-4DB5-9C49-066E4FE4752AQ26775094-1853C4C0-D3D1-4CB2-BB53-5DDA3032A654Q28077243-45FB39EF-FBE4-47AB-A979-A0B0CDEC47B2Q30456795-6B523692-CA2D-4721-A9EC-F2B97D8EF1E3Q33379276-FF6EC619-10AB-4E2D-A74A-5E7E1388BF08Q33710233-1E66D622-4D28-43CA-B058-C8D454B81152Q33951586-A8D1B0C6-8153-4333-B068-9C854C2AFEDEQ34111867-58B42865-5FBB-4748-BB72-10FB1CE88333Q34119028-6374A20E-1E87-49A9-8F2E-8B82FA67A3A3Q34248718-0A64EE9B-A4FE-4C29-A300-5E11359104A3Q34275213-EB18B208-B501-4AC5-B14E-DB1A69FBE64FQ34469248-73888DFE-EB42-421B-9DE3-5BA3D07C45F4Q34479003-494CB6D4-B333-41AA-B3AE-E583C31FA019Q34738030-DDD53A56-FA26-4281-ABBC-5753C37A5B5FQ34776574-6C8BFA52-BE94-4F5A-94E8-C9E3D411C435Q34978283-3E428FF1-D8C3-4DD2-AD27-CD6043368683Q35174533-D36732F6-C9DB-4B5B-8ABB-A906E34E2C87Q35572763-5FD38876-FC7C-4E10-8FF0-4ED45BA3FD38Q35573190-85B8FB9D-A82B-46B3-B180-1B24BD772D7FQ35941029-0492FAC2-D66F-4000-84A1-7CF53603F7F3Q36241882-822D06D7-D6F8-4215-A392-077401E6F2AAQ36605853-7AD490FC-00A9-4734-8DDF-BFFEF36C30D9Q36961178-AF0F8AB7-E3B3-47D9-B50A-C7B860977221Q37401543-B2329665-7B95-42C5-884C-34594CC9684BQ37531368-D35252CA-77D7-4C20-B77C-D6E2C368853EQ37696405-C8532B64-6563-4721-9D0E-8BC397697997Q37740954-7D48E209-B0E4-4515-80D8-74D92305B9D3Q37756397-B46E110B-43B9-42E5-895E-C08AE06BE295Q37853555-4ABA3CC6-1A1C-4D60-A29F-4E53074E24E7Q37970020-2412E5C0-AC1B-4C46-AC1E-3C09172E2CFEQ38818744-F18CA70B-908B-438F-9C87-580C4A376761Q39007492-54CC1F68-EB23-4678-919F-80D52A940F48Q39110866-FF6B0C91-0B47-4528-B871-AF68B6EE77F0Q40975730-AECE1D19-F25D-4815-BE12-FA0953FA0668Q42511044-0DE4DC63-266A-4CE0-926F-7B1E1BB6ADC9Q42881932-6F0E7A9E-C79E-46DF-AA31-D9BD4DEB03E4Q43416110-2830B2EC-EC6D-40C4-ADEC-C84F6EB04EF7Q51293206-A9641CE0-834C-408D-B906-58A9B47EC87FQ53293967-0E98D422-451A-4BB8-B4D2-06EF13BE53B4
P2860
Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Triple negative breast carcino ...... rofiling to clinical practice.
@en
Triple negative breast carcino ...... rofiling to clinical practice.
@nl
type
label
Triple negative breast carcino ...... rofiling to clinical practice.
@en
Triple negative breast carcino ...... rofiling to clinical practice.
@nl
prefLabel
Triple negative breast carcino ...... rofiling to clinical practice.
@en
Triple negative breast carcino ...... rofiling to clinical practice.
@nl
P2093
P1476
Triple negative breast carcino ...... rofiling to clinical practice.
@en
P2093
Leslie K Diaz
Nour Sneige
Vincent L Cryns
W Fraser Symmans
P304
P356
10.1097/PAP.0B013E3181594733
P577
2007-11-01T00:00:00Z